Neoadjuvant systemic treatment for breast cancer in Italy: The Italian Society of Surgical Oncology (SICO) Breast Oncoteam survey

Vicini, Elisa; Invento, Alessandra; Cuoghi, M.; Bafile, A.; Battaglia, C; Biglia, Nicoletta; Busani, M.; Bussone, Riccardo; Cianchetti, Ettore; Caruso, Francesco; Cucchi, M.C.; Dessena, M.; Filippo, F. Di; Fabi, N.; Folli, Secondo; Friedman, Daniele; Macellari, G; Mainente, P; Murgo, Roberto; Neri, Alessandro; Pollini, Giovanni Paolo; Palli, D.; Ricci, Fábio; Scalco, G.; Taffurelli, Mario; Trunfio, Martino; Galimberti, Viviana

doi:10.1016/j.ejso.2018.03.018

Cited by 5 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…are recommended ( Robert and Turner, 2019 ; Yang and Polley, 2019 ). However, long-term survival for this group of patients is dismal (less than 5%) ( Vicini et al, 2018 ; Yang and Polley, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

A DNA Methylation-Based Panel for the Prognosis and Diagnosis of Patients With Breast Cancer and Its Mechanisms

Hou

Chen

et al. 2020

Front. Mol. Biosci.

View full text Add to dashboard Cite

Objective To identify DNA methylation related biomarkers in patients with breast cancer (BC). Materials and Methods A total of seven BC methylation studies including 1,438 BC patients or breast tissues were included in this study. An elastic net regularized Cox proportional hazards regression (CPH) model was used to build a multi-5′-C-phosphate-G-3′ methylation panel. The diagnosis and prognosis power of the panel was evaluated and validated using a Kaplan–Meier curve, univariate and multivariable CPH, subgroup analysis. A nomogram containing the panel was developed. The relationships between the panel-based methylation risk and the immune landscape and genomic metrics were investigated. Results Sixty-eight CpG sites were significantly correlated with the overall survival (OS) of BC patients, and based on the result of penalized CPH, a 28-CpG site based multi CpG methylation panel was found. The prognosis and diagnosis role of the panel was validated in the discovery set, validation set, and six independent cohorts, which indicated that higher methylation risk was associated with poor OS, and the panel outperformed currently available biomarkers and remained an independent factor after adjusting for other clinical features. The methylation risk was negatively correlated with innated and adaptive immune cells, and positively correlated with total mutation load, SCNA, and MATH. Conclusions We validated a multi CpG methylation panel that could independently predict the OS of BC patients. The Th2-mediated tumor promotion effect—suppression of innate and adaptive immunity—participated in the progression of high-risk BC. Patients with high methylation risk were associated with tumor heterogeneity and poor survival.

show abstract

Section: Introductionmentioning

confidence: 99%

A DNA Methylation-Based Panel for the Prognosis and Diagnosis of Patients With Breast Cancer and Its Mechanisms

Hou

Chen

et al. 2020

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…For example, the rates of image-guided core needle biopsy and treatment with four cycles of adjuvant chemotherapy are only 34.1 and 12.1%, respectively, in China [8, 9]. A German study reported approximately 20% of patients treated with neoadjuvant therapy in the years 2009–2011 from a cohort of 39,570 patients and the treatment was recommended by the European Society of Breast Cancer Specialist (EUSOMA) [10, 11]. To ensure that actual treatment follows clinical guidelines, many institutions and professional organizations in various countries and regions have initiated great efforts to develop quality indicators for breast cancer and have applied these indicators to evaluate and monitor the quality of breast cancer care [12–15].…”

Section: Introductionmentioning

confidence: 99%

Factors analysis on the use of key quality indicators for narrowing the gap of quality of care of breast cancer

Wang

et al. 2019

BMC Cancer

View full text Add to dashboard Cite

BackgroundThere are differences in the quality of care among breast cancer patients. Narrowing the quality differences could be achieved by increasing the utilization rate of indicators. Here we explored key indicators that can improve the quality of care and factors that may affect the use of these indicators.MethodsA total of 3669 breast cancer patients were included in our retrospective study. We calculated patient quality-of-care composite score based on patient average method. Patients were divided into high- and low-quality groups according to the mean score. We obtained the indicators with large difference in utilization between the two groups. Multilevel logistic regression model was used to analyze the factors influencing quality of care and use of indicators.ResultsThe mean composite score was 0.802, and the number of patients in the high- and low-quality groups were 1898 and 1771, respectively. Four indicators showed a difference in utilization between the two groups of over 40%. Histological grade, pathological stage, tumor size and insurance type were the factors affecting the quality of care. In single indicator evaluation, besides the above factors, age, patient income and number of comorbidities may also affect the use of these four indicators. Number of comorbidities may have opposite effects on the use of different indicators, as does pathological stage.ConclusionsIdentifying key indicators for enhancing the quality-of-care of breast cancer patients and factors that affect the indicator adherence may provide guides for enhancing the utilization rate of these indicators in clinical practice.

show abstract

Neoadjuvant therapy for breast cancer

et al. 2019

View full text Add to dashboard Cite

Objective: To evaluate the frequency of neoadjuvant therapy (NT) in women with stage I–III breast cancer in Italy and whether it is influenced by biological characteristics, screening history, and geographic area. Methods: Data from the High Resolution Study conducted in 7 Italian cancer registries were used; they are a representative sample of incident cancers in the study period (2009–2013). Included were 3546 women aged <85 years (groups <50, 50–69, 70–64, and 75+) with stage I–III breast cancer at diagnosis who underwent surgery. Women were classified as receiving NT if they received chemotherapy, target therapy, and/or hormone therapy before the first surgical treatment. Logistic models were built to test the association with biological and contextual variables. Results: Only 8.2% of women (290 cases) underwent NT; the treatment decreases with increasing age (14.5% in age <50 and 2.2% in age 75+), is more frequent in women with negative receptors (14.8%), HER2-positive (15.7%), and triple-negative (15.6%). The multivariable analysis showed the probability of receiving NT is higher in stage III (odds ratio [OR] 3.83; 95% confidence interval [CI] 2.83–5.18), luminal B (OR 1.87; 95% CI 1.27–2.76), triple-negatives (OR 1.88; 95% CI 1.15–3.08), and in symptomatic cancers (OR 1.98; 95% CI 1.13–3.48). Use of NT varied among geographic areas: Reggio Emilia had the highest rates (OR 2.29; 95% CI 1.37–3.82) while Palermo had the lowest (OR 0.41; 95% CI 0.24–0.68). Conclusions: The use of NT in Italy is limited and variable. There are no signs of greater use in hospitals with more advanced care.

show abstract

Neoadjuvant systemic treatment for breast cancer in Italy: The Italian Society of Surgical Oncology (SICO) Breast Oncoteam survey

Cited by 5 publications

References 31 publications

A DNA Methylation-Based Panel for the Prognosis and Diagnosis of Patients With Breast Cancer and Its Mechanisms

A DNA Methylation-Based Panel for the Prognosis and Diagnosis of Patients With Breast Cancer and Its Mechanisms

Factors analysis on the use of key quality indicators for narrowing the gap of quality of care of breast cancer

Neoadjuvant therapy for breast cancer

Contact Info

Product

Resources

About